vonoprazan

Search documents
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
Globenewswire· 2025-10-06 12:00
Core Viewpoint - Phathom Pharmaceuticals has appointed Sanjeev Narula as Chief Financial and Business Officer to enhance its leadership team and support its growth strategy, particularly in achieving profitability and increasing shareholder value [1][2][7]. Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, specifically through its product VOQUEZNA, a potassium-competitive acid blocker [5]. Leadership Appointment - Sanjeev Narula brings extensive experience from his previous roles, including Chief Financial Officer at Intra-Cellular Therapies, where he played a significant role in its $14.6 billion acquisition by Johnson & Johnson [3]. - Narula has held senior finance positions at Pfizer, Viatris, and Upjohn, contributing to his expertise in capital strategy, M&A, and financial planning [4]. Product Information - VOQUEZNA is marketed in the U.S. for various gastrointestinal conditions, including heartburn associated with Non-Erosive GERD and as part of treatment for H. pylori infection [5].
凯雷Q2继续重仓航空维修巨头StandardAero(SARO.US) 清仓文远知行(WRD.US)
Zhi Tong Cai Jing· 2025-08-13 10:55
Core Insights - Carlyle Group Inc reported a total market value of $5.03 billion for its Q2 2025 holdings, reflecting a 32% increase from the previous quarter's $3.80 billion [1][2] - The investment portfolio saw only one new purchase, one addition, two reductions, and four complete sell-offs, indicating a highly concentrated stock holding with the top ten holdings accounting for 99.72% of the total market value [1][2] Holdings Summary - The largest holding is StandardAero Inc, with approximately 152.67 million shares valued at about $4.83 billion, representing 95.06% of the portfolio, and showing a 13.64% increase in shares from the previous quarter [2][5] - Soleno Therapeutics Inc is the second-largest holding, with around 860,980 shares valued at approximately $72.08 million, maintaining its share count from the previous quarter [3][5] - Phathom Pharmaceuticals ranks third, holding about 3.5 million shares valued at approximately $33.53 million, also unchanged from the previous quarter [3][5] - Pony.ai, a Chinese autonomous driving company, is the fourth-largest holding with approximately 2.36 million shares valued at about $31.18 million, showing no change in share count [4][5] - Invitation Homes Inc, focusing on single-family rental properties, is the fifth-largest holding with around 477,500 shares valued at approximately $15.66 million, also unchanged [4][5] Trading Activity - The largest purchase in Q2 was StandardAero Inc, while the only new position established was in Crowdstrike Holdings Inc, with a market value of approximately $6.26 million [5][6] - Major sell-offs included WeRide Inc, SEACOR Marine Holdings Inc, Complete Solaria Inc, and Spruce Biosciences Inc, with WeRide and SEACOR Marine being completely sold out [6][7]
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
Globenewswire· 2025-06-23 11:59
Core Insights - Phathom Pharmaceuticals has appointed Anne Marie Cook as Chief Legal Officer and Corporate Secretary, bringing extensive legal expertise in the pharmaceutical industry [1][2][3] Company Overview - Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal diseases [6] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), marketed in the U.S. as VOQUEZNA for various gastrointestinal conditions [6] Leadership Background - Anne Marie Cook has a strong background in pharmaceutical law, having served as Senior Vice President and General Counsel at Sage Therapeutics, and held legal leadership roles at Aegerion, ViaCell, and Biogen [2][4] - Cook's experience includes overseeing legal activities related to commercialization, regulatory compliance, intellectual property, and corporate governance [4] Strategic Vision - The CEO of Phathom, Steven Basta, expressed confidence that Cook's skills will significantly impact the company's growth and corporate strategy [3] - Cook emphasized her commitment to helping Phathom redefine the standard of care in acid-related gastrointestinal diseases and create value for stakeholders [3][4]
Phathom Pharmaceuticals(PHAT) - 2023 Q4 - Earnings Call Presentation
2025-06-19 09:06
Business Overview - VOQUEZNA aims to transform the landscape of acid-related disorders, targeting a US potential peak revenue opportunity of over $3 billion[11, 12] - The company is experiencing early success with its pricing and access strategy[20] - VOQUEZNA launch is off to a strong start, with over 14,000 total demand[18] Commercial Launch Progress - Over 3,800 filled VOQUEZNA scripts[18] - Over 1,200 unique VOQUEZNA writers[18] - The company has achieved approximately 38% commercial coverage, representing about 60 million commercial lives covered[21] Financial Results - The company had $3814 million in cash as of December 31, 2023[27] - Q4 2023 net revenues were $07 million[27] - Full Year 2023 Non-GAAP R&D expenses were $714 million, and Non-GAAP SG&A expenses were $1010 million[27] - Full Year 2023 GAAP net loss was ($201592) thousand, and Non-GAAP adjusted net loss was ($129713) thousand[29]
Phathom Pharmaceuticals(PHAT) - 2024 Q1 - Earnings Call Presentation
2025-06-19 09:06
Business Update - VOQUEZNA has achieved significant progress in clinical superiority, brand awareness, and patient access during its launch phase[10] - As of April 26, 2024, over 43,000 prescriptions have been written and over 17,500 prescriptions have been filled for VOQUEZNA[12] - VOQUEZNA has secured commercial coverage for approximately 72 million lives[13] - The company is preparing for a potential Non-Erosive GERD launch, with an action date of July 19, 2024, targeting a market of approximately 15 million adults[14] Commercial Launch Progress - Total VOQUEZNA demand includes over 43,000 unique prescriptions written and over 17,500 filled prescriptions[21] - The number of unique VOQUEZNA writers has reached over 3,800[21] - There has been consistent monthly growth in filled prescriptions, reaching approximately 7,520 as of April 26, 2024[26] - Commercial coverage has expanded to 48%, covering approximately 72 million lives, including Cigna Healthcare with over 9 million lives covered[28] Financial Results - Net revenues for Q1 2024 were $1.9 million[36] - Non-GAAP SG&A expenses for Q1 2024 were $57.6 million[40] - The company reported $322.2 million in cash and cash equivalents as of March 31, 2024, which is expected to fund operations through the end of 2026[43]
Phathom Pharmaceuticals(PHAT) - 2024 Q4 - Earnings Call Presentation
2025-06-19 09:05
Business Performance & Growth - VOQUEZNA achieved over 300,000 filled prescriptions launch-to-date[13, 24] - Commercial coverage exceeds 80%, covering over 120 million commercial lives[9, 41] - Primary Care Physicians (PCPs) are increasingly contributing to prescription growth, with a ~2x increase in PCP awareness[39] - Approximately 70% of prescriptions in Q4 were refills, indicating continued therapy[31] - HCPs reporting patient requests increased by over 55% since the Direct-to-Consumer (DTC) campaign launch[43] Financial Results - Q4 2024 net revenue reached $29.7 million, reflecting an ~81% increase from the previous quarter[50] - The company reported a GAAP net loss of ($74.451) million for Q4 2024 and ($334.326) million for the full year 2024[54] - Non-GAAP adjusted net loss was ($56.376) million for Q4 2024 and ($262.316) million for the full year 2024[54] - Cash and cash equivalents totaled $297.3 million as of December 31, 2024[55] Legal & Development - The FDA acknowledged the Citizen Petition on 12/11/24, related to VOQUEZNA Orange Book listings[16] - The company is developing a strategy for OTC acid control market, which generates ~$3 billion annually[15]